Nurix Therapeutics
NRIX· Manufacturing· Fiscal year ends in November
Arthur T. Sands is the CEO of Nurix Therapeutics and was paid $6.4M in FY2025 (Nov), up 10%.
Executives4
See all- 1Arthur T. SandsPresident, Chief Executive Officer and DirectorFY2025
- 2Gwenn M. HansenChief Scientific OfficerFY2025
- 3Hans van HouteChief Financial OfficerFY2025
- 4Christine RingChief Legal Officer and Chief Compliance OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allNurix Therapeutics paid its 4 named executives $13.4M in total in FY2025 (Nov). CEO Arthur T. Sands was paid $6.4M of that.
| Name | |||
|---|---|---|---|
| Arthur T. SandsPresident, Chief Executive Officer and Director | |||
| Gwenn M. HansenChief Scientific Officer | |||
| Hans van HouteChief Financial Officer | |||
| Christine RingChief Legal Officer and Chief Compliance Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers21
See allThe FY2025 (Nov) proxy of Nurix Therapeutics names 21 peer companies for pay. Pay versus performance data of Nurix Therapeutics for that year is not on file, so it has no rank.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Julia P. GregoryChair · 6 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Mar 27, 2026 | FY2025 |
| Annual report | 10-K | Jan 28, 2026 | FY2025 |
| Proxy statement | DEF 14A | Mar 28, 2025 | FY2024 |
| Annual report | 10-K | Jan 28, 2025 | FY2024 |
| Proxy statement | DEF 14A | Mar 27, 2024 | FY2023 |
| Annual report | 10-K | Feb 15, 2024 | FY2023 |
